Thus, the immunohistochemical assessment of 99 pancreatic cancer specimens revealed a higher number of lymph node metastases and a shorter median survival of patients with AXL-positive tumors (12 versus 18 months) in contrast to the AXL-negative group (50). This evidence concerns the gene AXL and pancreatic neoplasm.